Article

BRAF Mutation Correlates with Worse Local-regional Control Following Radiation Therapy in Patients with Stage III Melanoma

2021-04-13

Abstract excerpt

<title>Abstract</title> <p>Background In patients with stage III melanoma, the use of adjuvant radiation therapy (RT) after lymph node dissection (LND) may be currently considered in selected high-risk patients to improve local-regional control. Melanomas harbor <italic>BRAF</italic> mutations <italic>(BRAF</italic>+) in 40–50% of cases, the majority of which are on the V600E residue. This study sought to compar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a7c71ea2-f239-559d-baea-d27be4406538
DOI: 10.21203/rs.3.rs-369617/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

BRAF Mutation Correlates with Worse Local-regional Control Following Radiation Therapy in Patients with Stage III MelanomaDOI 10.21203/rs.3.rs-369617/v1Read

BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.Semantic proximity Read

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.Semantic proximity Read

Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.Semantic proximity Read

Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II-III Malignant Melanoma.Semantic proximity Read

French updated recommendations in Stage I to III melanoma treatment and management.Semantic proximity Read

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.Semantic proximity Read

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous MelanomaSemantic proximity Read

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.Semantic proximity Read

Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.Semantic proximity Read

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.Semantic proximity Read

Clinicopathological Characteristics of BRAF V600E Mutated Melanomas in the Dalmatian Region of Croatia.Semantic proximity Read

Metastatic melanoma: a regional review and future directions.Semantic proximity Read